Less Ads, More Data, More Tools Register for FREE

Pin to quick picksConcurrent Technologies Regulatory News (CNC)

Share Price Information for Concurrent Technologies (CNC)

Share Price is delayed by 15 minutes
Get Live Data
272.50    21.50 (8.57%)
Bid:
270.00
Ask:
275.00
Spread: 5.00 (1.852%)
Market Cap: £247.54m
CNC Live PriceLast checked at - London Stock Exchange

Intraday Concurrent Technologies Share Chart

Product Launch

5 Nov 2012 12:25

RNS Number : 3383Q
Concurrent Technologies PLC
05 November 2012
 



05 November 2012

Concurrent Technologies Plc

 

High throughput 3rd generation Intel® Core™ Processor AdvancedMC™

 

Concurrent Technologies Plc (the "Company"), a world leading specialist in the design and manufacture of high-end embedded computer products for critical applications in the defence, aerospace, telecommunications, transportation, scientific and industrial markets, is pleased to announce the launch of its latest high performance AdvancedMC™ (AMC) processor board. The AM 91x/x1x combines the power-efficient 3rd generation Intel® Core™ processor with enhanced PCI Express® (PCIe) backplane connectivity. This combination of raw processing power and data throughput capability delivers high bandwidth, non-blocking movement of processed data while still meeting thermal budgets.

 

Graphics performance capability can increase by 50% and CPU performance can increase by 15% while operating within the same thermal budget as earlier Intel® Core™ processor-based AMC products. The enhanced PCIe capability complements the increased processing power by effectively delivering double the bit rate of the previous generation PCIe.

 

The AM 91x/x1x processor board is ideal for MicroTCA® and AdvancedTCA® based telecommunications applications such as IPTV, digital media servers, media gateways, broadband, Long Term Evolution (LTE) or LTE-Advanced, wireless base stations as well as in test systems for wireline and wireless networks. The AM 91x/x1x is also suitable for medical, automation, and security applications where fast data processing is a key requirement.

 

Glen Fawcett, Managing Director, Concurrent Technologies Plc, commented:

 

"By leveraging the power-efficiency, processing power and high bandwidth communication capabilities offered by the 3rd generation Intel® Core™ processor, the AM 91x/x1x will enable our customers to meet the demands of compute intensive applications requiring a low latency, non-blocking quality of service."

 

Enquiries:

Concurrent Technologies PlcGlen Fawcett, Managing Director

 

+44 (0)1206 752 626

Newgate Threadneedle (Financial PR)Caroline Evans-Jones

Robyn McConnachie

+44 (0)207 653 9850

Cenkos Securities plc (NOMAD)Ken FlemingNeil McDonald

+44 (0)131 220 6939+44 (0)131 220 9771

 

Note to Editors:

 

About Concurrent Technologies Plc

 

Concurrent Technologies Plc develops and manufactures high-end embedded computer products for use in a wide range of high performance applications within the telecommunications, defence, security, telemetry, scientific and aerospace markets. Using Intel® processors, including the latest 3rd generation Intel® Core™ i7, 2nd generation Intel® Core™ i7, Intel® Core™ i7 processors, Intel® Xeon® and Atom™ processors, the Company offers a wide range of computer products which are designed to be compliant with industry specifications including those for products used in extremely harsh environments.

 

For more information on Concurrent Technologies Plc and its products please visit www.cct.co.uk

All trademarks, registered trademarks and trade names used in this announcement are the property of their respective owners.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
PRLBABTTMBBMBPT
Date   Source Headline
6th Sep 20187:00 amRNSNotification of Interim Results
8th Jun 20187:00 amRNSProduct Announcement
22nd May 20183:41 pmRNSAGM Statement
21st May 20187:00 amRNSProduct Announcement
30th Apr 20189:30 amRNSDistribution of Annual Report and Accounts
4th Apr 20187:00 amRNSResults for the year ended 31 December 2017
3rd Apr 20189:01 amRNSProduct Announcement
28th Mar 20184:03 pmRNSNotice of Results
27th Mar 20182:14 pmRNSProduct Announcement
8th Mar 20187:00 amRNSSecond Interim Dividend
26th Feb 201810:17 amRNSCorrection - Product Announcement
26th Feb 20187:00 amRNSProduct Announcement
21st Feb 20187:00 amRNSProduct Announcement
23rd Jan 20187:00 amRNSProduct Announcement
21st Dec 20177:00 amRNSPre-Close Trading Update
30th Nov 20171:29 pmRNSProduct Announcement
18th Sep 20177:00 amRNSInterim Results for the six months ended 30 Jun 17
5th Sep 20177:00 amRNSNotice of Results
26th Jun 20177:00 amRNSProduct Announcement
25th May 20172:57 pmRNSResult of AGM
9th May 20177:00 amRNSNotice of AGM
12th Apr 20172:08 pmRNSDistribution of Annual Report and Accounts
30th Mar 201711:18 amRNSHolding(s) in Company
29th Mar 20174:33 pmRNSHolding(s) in Company
24th Mar 20177:00 amRNSFinal Results
22nd Mar 20177:00 amRNSNotice of Results
2nd Mar 201710:11 amRNSProduct Announcement
24th Feb 20177:00 amRNSSecond Interim Dividend
30th Jan 20179:23 amRNSProduct Announcement
13th Jan 20179:30 amRNSHolding(s) in Company
13th Jan 20179:30 amRNSHolding(s) in Company
20th Dec 20162:36 pmRNSPre-Close Trading Update
16th Dec 20163:13 pmRNSDirector/PDMR Shareholding
1st Nov 20167:00 amRNSProduct Launch
29th Sep 20167:00 amRNSProduct Launch
22nd Sep 20162:45 pmRNSTotal Voting Rights
9th Sep 201612:05 pmRNSDirector/PDMR Shareholding
30th Aug 20165:05 pmRNSHolding(s) in Company
30th Aug 201612:59 pmRNSHolding(s) in Company
26th Aug 20167:00 amRNSInterim Results
19th Aug 20162:21 pmRNSNotice of Interim Results
22nd Jul 20161:55 pmRNSHolding(s) in Company
1st Jul 20167:00 amRNSTrading Update
1st Jun 20162:43 pmRNSTotal Voting Rights
19th May 201612:56 pmRNSAGM Statement
12th May 20165:18 pmRNSDirector/PDMR Shareholding
6th May 20167:00 amRNSProduct Launch
19th Apr 20163:51 pmRNSDirector/PDMR Shareholding
19th Apr 201612:10 pmRNSDirector/PDMR Shareholding
18th Apr 20162:14 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.